Why Trulieve Cannabis Earnings Matter For Investors Now

Trulieve Cannabis (TRLV) reported second quarter 2026 results on 7 August that combined a larger net loss with lower sales, while still funding expansion in key medical cannabis markets.

The company posted revenue of US$271 million for the quarter compared with US$302.1 million a year earlier, and reported a net loss of US$406 million versus US$13.8 million in the prior year period.

Trulieve Cannabis shares closed at US$8.75 on 8 August and have a 90 day share price return of 8.02%, while the 3 year total shareholder return is very large compared with the 5 year total shareholder return that declined 68.81%. This suggests momentum has built recently despite earlier weakness.

If Trulieve Cannabis’s earnings update has you reassessing the sector, it can help to see how other companies are priced and growing by checking out 19 top founder-led companies

Trulieve Cannabis now trades well below the average analyst price target and at a large discount to some intrinsic value estimates. Following the recent rebound, where might a reasonable fair value range sit for this stock?

Most Popular Narrative: 54.9% Undervalued

At a last close of $8.75, the most followed narrative for Trulieve Cannabis points to a fair value close to $19.42, which is a wide gap. That view rests heavily on how future earnings, margins and cash generation could change the story from today’s reported loss.

A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.

Trulieve Cannabis is being valued on a blueprint that leans heavily on margin expansion and a very different earnings profile several years out. It is worth examining how falling revenue assumptions are mapped to a higher earnings base and a specific future P/E that underpins that $19.42 fair value tag.

Result: Fair Value of $19.42 (UNDERVALUED)

However, this Trulieve Cannabis narrative still leans on regulatory shifts and expansion plans that may be slower, smaller, or more costly than analysts currently factor in.

Next Steps

The mixed tone around Trulieve Cannabis can be hard to weigh. Take a moment to review the numbers and sentiment yourself and decide how the balance of risk and reward looks in light of the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Trulieve Cannabis?

If Trulieve Cannabis has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with other stocks that fit clear, disciplined criteria.

• Target turnaround potential by scanning 20 elite penny stocks with strong financials that pair lower share prices with stronger balance sheets and business fundamentals than many investors might expect.
• Zero in on pricing gaps by reviewing 52 high quality undervalued stocks that combine solid cash generation with balance sheets that can support future plans.
• Prioritise resilience by checking 83 resilient stocks with low risk scores that score well on financial health and show fewer red flags in key risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.